GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Solid Biosciences SLDB · USD

Health Care · US listing · 🇺🇸 United States

Compare

7.02

+6.53%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Solid Biosciences

From its filings with the US Securities and Exchange Commission

SEC filings

Solid Biosciences is based in Charlestown, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker SLDB. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2022, it reported revenue of $8.1m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
26 Jan 2018
Employees
121
Head office
500 RUTHERFORD AVENUE, CHARLESTOWN, MA, 02129
Incorporated in
DE
Classification
Biological Products, (No Diagnostic Substances)
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Mr. Ian SmithExecutive Chairman of the Board, since 2020$449,161
  • Mr. Alexander CumboPresident, Chief Executive Officer, Director, since 2022$4.9m
  • Mr. Ilan GanotCo-Founder, Director, since 2013$505,349
  • Mr. Kevin TanChief Financial Officer, Treasurer$1.3m
  • Mr. David HowtonChief Operating Officer, General Counsel, secretary$2.6m
  • Mr. Paul HerzichChief Technology Officer
  • Dr. Gabriel BrooksChief Medical Officer$2.1m
  • Dr. Jessie HanrahanChief Regulatory Officer
  • Mr. Adam StoneLead Independent Director$279,704
  • Dr. Martin FreedIndependent Director$284,204
  • Dr. Clare KahnIndependent Director$275,704
  • Dr. Georgia KerestyIndependent Director$273,451

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
42
Environment
43
Social
62
Governance
22
Carbon reduction policy
No
Human rights policy
No

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Solid Biosciences has a focused pipeline for Duchenne muscular dystrophy.
  • The company utilizes novel capsid libraries for its gene transfer candidates.
  • AVB-202 targets Friedreichs ataxia with a gene transfer candidate.

Weaknesses

  • The firm employs only 87 full-time staff members.
  • Operations are concentrated in a single location in Charlestown.
  • The company relies on early-stage development programs.

Opportunities

  • AVB-401 addresses BAG3 mediated dilated cardiomyopathy.
  • Dual gene expression technology allows packaging multiple transgenes.
  • SGT-003 targets cardiac and respiratory muscles specifically.

Threats

  • The biotechnology sector faces high regulatory hurdles.
  • Competitors may develop superior gene transfer vectors.
  • Clinical trial outcomes for SGT-001 remain uncertain.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.